Published in Cell Immunol on August 01, 2003
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell (2005) 2.37
Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J Exp Med (2004) 1.32
Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function. J Immunol (2004) 1.21
In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy. J Immunol (2004) 0.98
Dendritic cells program non-immunogenic prostate-specific T cell responses beginning at early stages of prostate tumorigenesis. Prostate (2007) 0.94
Steady state dendritic cells present parenchymal self-antigen and contribute to, but are not essential for, tolerization of naive and Th1 effector CD4 cells. J Immunol (2007) 0.85
T-bet down-modulation in tolerized Th1 effector CD4 cells confers a TCR-distal signaling defect that selectively impairs IFN-gamma expression. J Immunol (2006) 0.85
Antibodies generated against conserved antigens expressed by bacteria and allergen-bearing fungi suppress airway disease. J Immunol (2012) 0.85
Tolerization of an established alphaB-crystallin-reactive T-cell response by intravenous antigen. Immunology (2007) 0.83
Peripheral Tolerization of Effector and Memory T Cells: Implications for Autoimmunity and Tumor-Immunity. Curr Immunol Rev (2005) 0.79
The E3 ubiquitin ligase Cbl-b regulates expansion but not functional activity of self-reactive CD4 T cells. J Immunol (2009) 0.79
Histone acetylation at the Ifng promoter in tolerized CD4 cells is associated with increased IFN-gamma expression during subsequent immunization to the same antigen. J Immunol (2007) 0.78
The central role of CD4(+) T cells in the antitumor immune response. J Exp Med (1998) 6.02
Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell (1995) 5.82
Helper T cell differentiation is controlled by the cell cycle. Immunity (1998) 5.71
A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity (1996) 5.64
Modulation of chromatin structure regulates cytokine gene expression during T cell differentiation. Immunity (1998) 5.38
The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity (1998) 5.20
Thymic selection of CD8+ single positive cells with a class II major histocompatibility complex-restricted receptor. J Exp Med (1994) 4.91
Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci U S A (1998) 4.53
T(H) cell differentiation is accompanied by dynamic changes in histone acetylation of cytokine genes. Nat Immunol (2002) 4.38
Distinct lineages of T(H)1 cells have differential capacities for memory cell generation in vivo. Nat Immunol (2002) 4.00
Chlamydia infections and heart disease linked through antigenic mimicry. Science (1999) 3.73
Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science (1998) 3.68
The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev (2002) 3.28
CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity (2000) 3.07
Cutting edge: changes in histone acetylation at the IL-4 and IFN-gamma loci accompany Th1/Th2 differentiation. J Immunol (2002) 3.04
CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J Exp Med (1998) 2.69
Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med (1994) 2.33
A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol (2002) 2.31
CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity (1999) 2.25
Interferon-gamma is essential for destruction of beta cells and development of insulin-dependent diabetes mellitus. J Exp Med (1997) 1.67
Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur J Immunol (1996) 1.49
Virus-induced autoimmune diabetes: most beta-cells die through inflammatory cytokines and not perforin from autoreactive (anti-viral) cytotoxic T-lymphocytes. Diabetes (2000) 1.38
In vivo CD4+ T cell tolerance induction versus priming is independent of the rate and number of cell divisions. J Immunol (2000) 1.36
Analysis of the relationship between viral infection and autoimmune disease. Immunity (2001) 1.32
Enrichment and detection of live antigen-specific CD4(+) and CD8(+) T cells based on cytokine secretion. Eur J Immunol (1999) 1.31
The temporal importance of TNFalpha expression in the development of diabetes. Immunity (2000) 1.27
Memory CD8(+) T cells undergo peripheral tolerance. Immunity (2002) 1.16
Restricted clonal expression of IL-2 by naive T cells reflects differential dynamic interactions with dendritic cells. J Exp Med (2003) 1.14
CD4 cell priming and tolerization are differentially programmed by APCs upon initial engagement. J Immunol (2002) 1.13
Effector CD4 cells are tolerized upon exposure to parenchymal self-antigen. J Immunol (2002) 1.08
TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells. J Immunol (2003) 1.00
Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy. J Immunol (2001) 0.97
Identification of a cross-reactive self ligand in virus-mediated autoimmunity. Eur J Immunol (1999) 0.83
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell (2005) 2.37
Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells. Blood (2012) 1.95
Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome. Nat Genet (2013) 1.79
Tc17 CD8 T cells: functional plasticity and subset diversity. J Immunol (2009) 1.54
Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study. Am J Hum Genet (2012) 1.41
CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation. J Immunol (2011) 1.36
Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function. J Immunol (2004) 1.21
CD4+ T cells pass through an effector phase during the process of in vivo tolerance induction. J Immunol (2003) 1.19
Evaluation of the genetic association of the PTPN22 R620W polymorphism in familial and sporadic systemic lupus erythematosus. Arthritis Rheum (2006) 1.14
CD4 cell priming and tolerization are differentially programmed by APCs upon initial engagement. J Immunol (2002) 1.13
Cutting edge: Paracrine, but not autocrine, IL-2 signaling is sustained during early antiviral CD4 T cell response. J Immunol (2006) 1.09
Effector CD4 cells are tolerized upon exposure to parenchymal self-antigen. J Immunol (2002) 1.08
Presensitizing with a Toll-like receptor 3 ligand impairs CD8 T-cell effector differentiation and IL-33 responsiveness. Proc Natl Acad Sci U S A (2012) 1.01
In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy. J Immunol (2004) 0.98
Association of two independent functional risk haplotypes in TNIP1 with systemic lupus erythematosus. Arthritis Rheum (2012) 0.96
Dendritic cells program non-immunogenic prostate-specific T cell responses beginning at early stages of prostate tumorigenesis. Prostate (2007) 0.94
Self-antigen prevents CD8 T cell effector differentiation by CD134 and CD137 dual costimulation. J Immunol (2008) 0.93
The IKK-neutralizing compound Bay11 kills supereffector CD8 T cells by altering caspase-dependent activation-induced cell death. J Leukoc Biol (2008) 0.85
Steady state dendritic cells present parenchymal self-antigen and contribute to, but are not essential for, tolerization of naive and Th1 effector CD4 cells. J Immunol (2007) 0.85
T-bet down-modulation in tolerized Th1 effector CD4 cells confers a TCR-distal signaling defect that selectively impairs IFN-gamma expression. J Immunol (2006) 0.85
CD134/CD137 dual costimulation-elicited IFN-γ maximizes effector T-cell function but limits Treg expansion. Immunol Cell Biol (2013) 0.84
In vitro and in vivo differentiated effector CD8 T cells display divergent histone acetylation patterns within the Ifng locus. Immunol Lett (2009) 0.83
Blood feeding by the Rocky Mountain spotted fever vector, Dermacentor andersoni, induces interleukin-4 expression by cognate antigen responding CD4+ T cells. Parasit Vectors (2009) 0.80
The E3 ubiquitin ligase Cbl-b regulates expansion but not functional activity of self-reactive CD4 T cells. J Immunol (2009) 0.79
Histone acetylation at the Ifng promoter in tolerized CD4 cells is associated with increased IFN-gamma expression during subsequent immunization to the same antigen. J Immunol (2007) 0.78